


al., Free Radical Biology & Medicine 52 (2012) 444–451 or R.Steel et al., Med. Chem. Lett. 2012, 3, 407–410).

It has been found, however, that the peptides containing the DXETGE sequence cannot cross cell membranes easily. In order to improve permeation ability of these compounds, conjugation with a fatty acid (for ex., a stearyl residue) or a cell penetrating peptide (for example, the HIV-TAT sequence) is required.

Summary

The present inventors have found that a cyclic heterodetic sequence containing an aromatic structure linked to the high affinity sequence through one or two cysteines has an improved binding affinity with respect to similar homodetic cyclic peptides.

Accordingly in one aspect, the present disclosure provides a peptidic compound, which peptidic compound is a compound of formula (I)', or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof:



Formula (I)'


wherein

- R¹ represents a hydrogen atom, a -CO(C₁-C₄ alkyl) group, a -CONH(C₁-C₄ alkyl) group or a -Aa₇₅-Aa₇₄-[L₁]_m-[Tag₁]_n group;
- R² represents a -OH group, a -NH₂ group, or a -Aa₈₄-Aa₈₅-[L₂]_p-[Tag₂]_q group;
- Aa₇₄ represents a direct bond, a leucine, a valine, a lysine, an arginine, a phenylalanine, a proline or a N-acetyl-proline residue, wherein when Aa₇₄ is other than a direct bond: (a) Aa₇₄ is optionally linked to Aa₈₅; and/or (b) Aa₇₄ is

optionally alkylated with a C₁-C₄ alkyl group on the N at the peptidic bond, and wherein when Aa₇₄ is a proline or a N-acetyl-proline residue it is unsubstituted or substituted by a -NH₂ group or a -NHC(O)CH₃ group;

- Aa₇₅ represents a direct bond, a glutamine, a leucine, a lysine, a valine, a phenylalanine or an arginine residue, wherein when Aa₇₅ is other than a direct bond Aa₇₅ is optionally alkylated with a C₁-C₄ alkyl group on the N at the peptidic bond;
- m and n each independently represent an integer selected from 0 and 1, wherein when m and n each represent 0 and Aa₇₄ is not linked to Aa₈₅, the or each amino-terminal group of R¹ is a -NH₂ group or a -NHC(O)CH₃ group and provided that when m and n each represent 0, Aa₇₄ and Aa₇₅ cannot simultaneously be a direct bond;
- when m is 1 and n is 1 L₁ represents a -C(O)-(CH₂)₍₁₋₄₎-NH- group and when m is 1 and n is 0 L₁ represents a -C(O)-(CH₂)₍₁₋₄₎-NH₂ group;
- Tag₁ represents a -C(O)-(CH₂)_r-CH₃ group or a -C(O)-(CH₂)₇-(CH=CH-CH₂)₁₋₃-(CH₂)₀₋₆-CH₃ group, wherein when Aa₇₄ represents a 4-aminoproline or a 4-amino-N-acetyl-proline residue and m is 0, the Tag₁ group is linked to Aa₇₄ through the 4-amino substituent of the 4-aminoproline residue or through the 4-amino substituent of the 4-amino-N-acetyl-proline residue;
- r represents an integer selected from 6 to 24;
- Aa₈₄ represents a direct bond, a leucine, a valine, a lysine or an arginine residue, wherein, when Aa₈₄ is other than a direct bond, Aa₈₄ is optionally alkylated with a C₁-C₄ alkyl group on the N at the peptidic bond;
- Aa₈₅ represents a direct bond, a proline, a leucine, a valine, a lysine, an arginine, or a D-proline residue, wherein when Aa₈₅ is other than a direct bond: (a) Aa₈₅ is optionally linked to Aa₇₄; and/or (b) Aa₈₅ is optionally alkylated with a C₁-C₄ alkyl group on the N at the peptidic bond;
- p and q each independently represent an integer selected from 0 and 1, wherein, when p and q each represent 0 and Aa₇₄ is not linked to Aa₈₅, the or each carboxy-terminal group of R² is a -COOH group or a -CONH₂ group and provided that when p and q each represent 0, Aa₈₄ and Aa₈₅ cannot simultaneously be a direct bond;

- when p is 1 and q is 1 L₂ represents a –NH-(CH₂)₍₁₋₄₎-CO- group and when p is 1 and q is 0 L₂ represents a –NH-(CH₂)₍₁₋₄₎-COOH or a –NH-(CH₂)₍₁₋₄₎-CONH₂ group;
 - Tag₂ represents a peptide containing from 6 to 20 amino acids wherein at least three of these amino acids are selected from the group consisting of lysine and arginine, wherein the or each carboxy-terminal group of Tag₂ is a -COOH group or a -CONH₂ group;
 - s represents 0 or 1;
 - t represents 0 or 1;
 - u represents 0 or 1;
 - Aa₇₈ represents a proline, a L-thioprolin, an alanine, a phenylalanine, an arginine or a glutamic acid residue, wherein the proline, L-thioprolin, alanine, phenylalanine, arginine or glutamic acid residue is optionally substituted by one, two or three substituents selected from a halogen atom and amino group and wherein Aa₇₈ is optionally alkylated with a C₁-C₄ alkyl group on the N at the peptidic bond; and
 - G₁ represents a C₆₋₂₀ aryl group selected from a phenyl group, a naphthyl group, a biphenyl group and a binaphthyl group; or a 6-10 membered heteroaryl group selected from a pyridine group, an indolyl group and a quinoxaline group; wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from a C₁-C₄ alkyl group and a halogen atom; or a 4-6 membered saturated heterocyclyl group containing one oxygen atom selected from an oxetanyl group, a tetrahydrofuranyl group and a tetrahydro-2H-pyranyl group.
- Accordingly the present disclosure also provides a peptidic compound, which peptidic compound is a compound of formula (I), or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof:



wherein

- R^1 represents a hydrogen atom, a $-\text{CO}(\text{C}_1\text{-C}_4 \text{ alkyl})$ group, a $-\text{CONH}(\text{C}_1\text{-C}_4 \text{ alkyl})$ group or a $-\text{Aa}_{75}\text{-Aa}_{74}\text{-}[\text{L}_1]_m\text{-}[\text{Tag}_1]_n$ group;
- R^2 represents a $-\text{OH}$ group, a $-\text{NH}_2$ group, or a $-\text{Aa}_{84}\text{-Aa}_{85}\text{-}[\text{L}_2]_p\text{-}[\text{Tag}_2]_q$ group;
- Aa_{74} represents a direct bond, a leucine, a valine, a lysine, an arginine, a phenylalanine, a proline or a N-acetyl-proline residue, wherein when Aa_{74} is other than a direct bond: (a) Aa_{74} is optionally linked to Aa_{85} ; and/or (b) Aa_{74} is optionally alkylated with a $\text{C}_1\text{-C}_4$ alkyl group on the N at the peptidic bond, and wherein when Aa_{74} is a proline or a N-acetyl-proline residue it is unsubstituted or substituted by a $-\text{NH}_2$ group or a $-\text{NHC}(\text{O})\text{CH}_3$ group;
- Aa_{75} represents a direct bond, a glutamine, a leucine, a lysine, a valine, a phenylalanine or an arginine residue, wherein when Aa_{75} is other than a direct bond Aa_{75} is optionally alkylated with a $\text{C}_1\text{-C}_4$ alkyl group on the N at the peptidic bond;
- m and n each independently represent an integer selected from 0 and 1, wherein when m and n each represent 0 and Aa_{74} is not linked to Aa_{85} , the or each amino-terminal group of R^1 is a $-\text{NH}_2$ group or a $-\text{NHC}(\text{O})\text{CH}_3$ group and provided that when m and n each represent 0, Aa_{74} and Aa_{75} cannot simultaneously be a direct bond;
- when m is 1 and n is 1 L_1 represents a $-\text{C}(\text{O})\text{-(CH}_2\text{)}_{(1-4)}\text{-NH-}$ group and when m is 1 and n is 0 L_1 represents a $-\text{C}(\text{O})\text{-(CH}_2\text{)}_{(1-4)}\text{-NH}_2$ group;

- Tag₁ represents a $-\text{C}(\text{O})-(\text{CH}_2)_r-\text{CH}_3$ group, wherein when Aa₇₄ represents a 4-aminoproline or a 4-amino-N-acetyl-proline residue and m is 0, the Tag₁ group is linked to Aa₇₄ through the 4-amino substituent of the 4-aminoproline residue or through the 4-amino substituent of the 4-amino-N-acetyl-proline residue;
- 5 • r represents an integer selected from 6 to 18;
- Aa₈₄ represents a direct bond, a leucine, a valine, a lysine or an arginine residue, wherein, when Aa₈₄ is other than a direct bond, Aa₈₄ is optionally alkylated with a C₁-C₄ alkyl group on the N at the peptidic bond;
- Aa₈₅ represents a direct bond, a proline, a leucine, a valine, a lysine, an arginine,
10 or a D-proline residue, wherein when Aa₈₅ is other than a direct bond: (a) Aa₈₅ is optionally linked to Aa₇₄; and/or (b) Aa₈₅ is optionally alkylated with a C₁-C₄ alkyl group on the N at the peptidic bond;
- p and q each independently represent an integer selected from 0 and 1, wherein,
15 when p and q each represent 0 and Aa₇₄ is not linked to Aa₈₅, the or each carboxy-terminal group of R² is a -COOH group or a -CONH₂ group and provided that when p and q each represent 0, Aa₈₄ and Aa₈₅ cannot simultaneously be a direct bond;
- when p is 1 and q is 1 L₂ represents a $-\text{NH}-(\text{CH}_2)_{(1-4)}-\text{CO}-$ group and when p is 1 and q is 0 L₂ represents a $-\text{NH}-(\text{CH}_2)_{(1-4)}-\text{COOH}$ or a $-\text{NH}-(\text{CH}_2)_{(1-4)}-\text{CONH}_2$
20 group;
- Tag₂ represents a peptide containing from 6 to 20 amino acids wherein at least three of these amino acids are selected from the group consisting of lysine and arginine, wherein the or each carboxy-terminal group of Tag₂ is a -COOH group or a -CONH₂ group;
- 25 • s represents 0 or 1;
- t represents 0 or 1;
- u represents 0 or 1;
- Aa₇₈ represents a proline, an alanine, a phenylalanine, an arginine or a glutamic acid residue, wherein the proline, alanine, phenylalanine, arginine or glutamic
30 acid residue is optionally substituted by one, two or three substituents selected from a halogen atom and amino group and wherein Aa₇₈ is optionally alkylated with a C₁-C₄ alkyl group on the N at the peptidic bond; and

- G₁ represents a C₆₋₂₀ aryl group selected from a phenyl group, a naphthyl group, a biphenyl group and a binaphthyl group; or a 6-10 membered heteroaryl group selected from a pyridine group, an indolyl group and a quinoxaline group; wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from a C₁-C₄ alkyl group and a halogen atom.

In another aspect, the disclosure also provides a pharmaceutical composition comprising a peptidic compound as defined herein together with one or more pharmaceutically acceptable carriers and/or excipients.

In yet another aspect, the disclosure refers to a peptidic compound as defined herein or a pharmaceutical composition as defined herein for use in therapy.

In yet another aspect, the disclosure refers to a peptidic compound as defined herein or a pharmaceutical composition as defined herein for use in therapy for the treatment of a pathological condition or disease associated with the activation of the Nrf2 pathway.

In yet another aspect, the disclosure refers to the Use of a peptidic compound as defined herein or a pharmaceutical composition as defined herein in the manufacture of a medicament for treating a pathological condition or disease selected from the group consisting of Parkinson's disease, depression, Alzheimer's disease, atherosclerosis, heart failure, myocardial infarction, diabetes, cancer, COPD, COPD exacerbations, acute lung injury, radiation-induced dermatitis, chemical induced dermatitis, contact induced dermatitis, Epidermolysis bullosa simplex, Pachyonychia congenital, Hailey-Hailey, vitiligo, photoaging and photodamaged skin.

Also provided by the disclosure is a peptidic compound as defined herein or a pharmaceutical composition as defined herein for use in a method of treatment of a human or animal body by therapy.

The disclosure also provides a peptidic compound as defined herein or a pharmaceutical composition as defined herein for use in treatment of a pathological condition or disease associated with the activation of the Nrf2 pathway.

Also provided by the disclosure is a method of treating a subject afflicted with a pathological condition or disease as defined herein, which comprises administering to said subject an effective amount of a peptidic compound as defined herein or a pharmaceutical composition as defined herein.

Further provided by the disclosure is the use of a peptidic compound as defined herein or a pharmaceutical composition as defined herein in the manufacture of a medicament for the treatment of a pathological condition or disease as defined herein.

5 **Details Description of the Invention**


10 The term amino acid, as used herein, refers to any one of the twenty standard amino acids, as listed below, or to the equivalent D-amino acid, or to N-acetyl-proline or to L-thioprolin (Thz) or to D-thioprolin. Preferably, the term amino acid refers to any one of the twenty standard aminoacids or D-proline or N-acetyl-proline or L-thioprolin.

As used herein, L-thioprolin (Thz) refers to (4*R*)-4-thiazolidinecarboxylic acid.

15 In another embodiment, the term amino acid, as used herein, refers to any one of the twenty standard amino acids, as listed below, or to the equivalent D-amino acid, or to N-acetyl-proline. Preferably, the term amino acid refers to any one of the twenty standard amino acids or D-proline or N-acetyl-proline.

Claims

1. A peptidic compound, which peptidic compound is a compound of formula (I)', or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof:



Formula (I)'

wherein

- R^1 represents a hydrogen atom, a $-\text{CO}(\text{C}_1\text{-C}_4 \text{ alkyl})$ group, a $-\text{CONH}(\text{C}_1\text{-C}_4 \text{ alkyl})$ group or a $-\text{Aa}_{75}\text{-Aa}_{74}\text{-}[\text{L}_1]_m\text{-}[\text{Tag}_1]_n$ group;
- R^2 represents a $-\text{OH}$ group, a $-\text{NH}_2$ group, or a $-\text{Aa}_{84}\text{-Aa}_{85}\text{-}[\text{L}_2]_p\text{-}[\text{Tag}_2]_q$ group;
- Aa_{74} represents a direct bond, a leucine, a valine, a lysine, an arginine, a phenylalanine, a proline or a N-acetyl-proline residue, wherein when Aa_{74} is other than a direct bond: (a) Aa_{74} is optionally linked to Aa_{85} ; and/or (b) Aa_{74} is optionally alkylated with a $\text{C}_1\text{-C}_4$ alkyl group on the N at the peptidic bond, and wherein when Aa_{74} is a proline or a N-acetyl-proline residue it is unsubstituted or substituted by a $-\text{NH}_2$ group or a $-\text{NHC}(\text{O})\text{CH}_3$ group;
- Aa_{75} represents a direct bond, a glutamine, a leucine, a lysine, a valine, a phenylalanine or an arginine residue, wherein when Aa_{75} is other than a direct bond Aa_{75} is optionally alkylated with a $\text{C}_1\text{-C}_4$ alkyl group on the N at the peptidic bond;
- m and n each independently represent an integer selected from 0 and 1, wherein when m and n each represent 0 and Aa_{74} is not linked to Aa_{85} , the amino-terminal group of R^1 is a $-\text{NH}_2$ group or a $-\text{NHC}(\text{O})\text{CH}_3$ group and

provided that when m and n each represent 0, Aa₇₄ and Aa₇₅ cannot simultaneously be a direct bond;

- when m is 1 and n is 1 L₁ represents a $-\text{C}(\text{O})-(\text{CH}_2)_{(1-4)}-\text{NH}-$ group and when m is 1 and n is 0 L₁ represents a $-\text{C}(\text{O})-(\text{CH}_2)_{(1-4)}-\text{NH}_2$ group;

- 5
- Tag₁ represents a $-\text{C}(\text{O})-(\text{CH}_2)_r-\text{CH}_3$ group or a $-\text{C}(\text{O})-(\text{CH}_2)_7-(\text{CH}=\text{CH}-\text{CH}_2)_{1-3}-(\text{CH}_2)_{0-6}-\text{CH}_3$ group, wherein when Aa₇₄ represents a 4-aminoproline or a 4-amino-N-acetyl-proline residue and m is 0, the Tag₁ group is linked to Aa₇₄ through the 4-amino substituent of the 4-aminoproline residue or through the 4-amino substituent of the 4-amino-N-acetyl-proline residue;

- 10
- r represents an integer selected from 6 to 24;
 - Aa₈₄ represents a direct bond, a leucine, a valine, a lysine or an arginine residue, wherein, when Aa₈₄ is other than a direct bond, Aa₈₄ is optionally alkylated with a C₁-C₄ alkyl group on the N at the peptidic bond;
 - Aa₈₅ represents a direct bond, a proline, a leucine, a valine, a lysine, an arginine,
- 15
- or a D-proline residue, wherein when Aa₈₅ is other than a direct bond: (a) Aa₈₅ is optionally linked to Aa₇₄; and/or (b) Aa₈₅ is optionally alkylated with a C₁-C₄ alkyl group on the N at the peptidic bond;
 - p and q each independently represent an integer selected from 0 and 1, wherein, when p and q each represent 0 and Aa₇₄ is not linked to Aa₈₅, the or each
- 20
- carboxy-terminal group of R² is a -COOH group or a -CONH₂ group and provided that when p and q each represent 0, Aa₈₄ and Aa₈₅ cannot simultaneously be a direct bond;


- when p is 1 and q is 1 L₂ represents a $-\text{NH}-(\text{CH}_2)_{(1-4)}-\text{CO}-$ group and when p is 1 and q is 0 L₂ represents a $-\text{NH}-(\text{CH}_2)_{(1-4)}-\text{COOH}$ or a $-\text{NH}-(\text{CH}_2)_{(1-4)}-\text{CONH}_2$ group;

- 25
- Tag₂ represents a peptide containing from 6 to 20 amino acids wherein at least three of these amino acids are selected from the group consisting of lysine and arginine, wherein the or each carboxy-terminal group of Tag₂ is a -COOH group or a -CONH₂ group;

- 30
- s represents 0 or 1;
 - t represents 0 or 1;
 - u represents 0 or 1;

- Aa₇₈ represents a proline, a L-thioprolino, an alanine, a phenylalanine, an arginine or a glutamic acid residue, wherein the proline, L-thioprolino, alanine, phenylalanine, arginine or glutamic acid residue is optionally substituted by one, two or three substituents selected from a halogen atom and amino group and wherein Aa₇₈ is optionally alkylated with a C₁-C₄ alkyl group on the N at the peptidic bond; and
- G₁ represents a C₆₋₂₀ aryl group selected from a phenyl group, a naphthyl group, a biphenyl group and a binaphthyl group; or a 6-10 membered heteroaryl group selected from a pyridine group, an indolyl group and a quinoxaline group; wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from a C₁-C₄ alkyl group and a halogen atom; or a 4-6 membered saturated heterocyclyl group containing one oxygen atom selected from an oxetanyl group, a tetrahydrofuranyl group and a tetrahydro-2H-pyranyl group.

2. A peptidic compound according to claim 1, which peptidic compound is a compound of formula (I), or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof:



Formula (I)

wherein

- R^1 represents a hydrogen atom, a $-\text{CO}(\text{C}_1\text{-C}_4 \text{ alkyl})$ group, a $-\text{CONH}(\text{C}_1\text{-C}_4 \text{ alkyl})$ group or a $-\text{Aa}_{75}\text{-Aa}_{74}\text{-}[\text{L}_1]_m\text{-}[\text{Tag}_1]_n$ group;
- R^2 represents a $-\text{OH}$ group, a $-\text{NH}_2$ group, or a $-\text{Aa}_{84}\text{-Aa}_{85}\text{-}[\text{L}_2]_p\text{-}[\text{Tag}_2]_q$ group;
- Aa_{74} represents a direct bond, a leucine, a valine, a lysine, an arginine, a
5 phenylalanine, a proline or a N-acetyl-proline residue, wherein when Aa_{74} is
other than a direct bond: (a) Aa_{74} is optionally linked to Aa_{85} ; and/or (b) Aa_{74} is
optionally alkylated with a $\text{C}_1\text{-C}_4$ alkyl group on the N at the peptidic bond, and
wherein when Aa_{74} is a proline or a N-acetyl-proline residue it is unsubstituted
or substituted by a $-\text{NH}_2$ group or a $-\text{NHC}(\text{O})\text{CH}_3$ group;
- Aa_{75} represents a direct bond, a glutamine, a leucine, a lysine, a valine, a
10 phenylalanine or an arginine residue, wherein when Aa_{75} is other than a direct
bond Aa_{75} is optionally alkylated with a $\text{C}_1\text{-C}_4$ alkyl group on the N at the
peptidic bond;
- m and n each independently represent an integer selected from 0 and 1, wherein
15 when m and n each represent 0 and Aa_{74} is not linked to Aa_{85} , the or each
amino-terminal group of R^1 is a $-\text{NH}_2$ group or a $-\text{NHC}(\text{O})\text{CH}_3$ group and
provided that when m and n each represent 0, Aa_{74} and Aa_{75} cannot
simultaneously be a direct bond;
- when m is 1 and n is 1 L_1 represents a $-\text{C}(\text{O})\text{-(CH}_2\text{)}_{(1-4)}\text{-NH-}$ group and when m
20 is 1 and n is 0 L_1 represents a $-\text{C}(\text{O})\text{-(CH}_2\text{)}_{(1-4)}\text{-NH}_2$ group;
- Tag_1 represents a $-\text{C}(\text{O})\text{-(CH}_2\text{)}_r\text{-CH}_3$ group, wherein when Aa_{74} represents a 4-
aminoproline or a 4-amino-N-acetyl-proline residue and m is 0, the Tag_1 group
is linked to Aa_{74} through the 4-amino substituent of the 4-aminoproline residue
or through the 4-amino substituent of the 4-amino-N-acetyl-proline residue;
- r represents an integer selected from 6 to 18;
- Aa_{84} represents a direct bond, a leucine, a valine, a lysine or an arginine residue,
wherein, when Aa_{84} is other than a direct bond, Aa_{84} is optionally alkylated with
a $\text{C}_1\text{-C}_4$ alkyl group on the N at the peptidic bond;
- Aa_{85} represents a direct bond, a proline, a leucine, a valine, a lysine, an arginine,
30 or a D-proline residue, wherein when Aa_{85} is other than a direct bond: (a) Aa_{85} is
optionally linked to Aa_{74} ; and/or (b) Aa_{85} is optionally alkylated with a $\text{C}_1\text{-C}_4$
alkyl group on the N at the peptidic bond;

- p and q each independently represent an integer selected from 0 and 1, wherein, when p and q each represent 0 and Aa₇₄ is not linked to Aa₈₅, the or each carboxy-terminal group of R² is a -COOH group or a -CONH₂ group and provided that when p and q each represent 0, Aa₈₄ and Aa₈₅ cannot simultaneously be a direct bond;
- when p is 1 and q is 1 L₂ represents a -NH-(CH₂)₍₁₋₄₎-CO- group and when p is 1 and q is 0 L₂ represents a -NH-(CH₂)₍₁₋₄₎-COOH or a -NH-(CH₂)₍₁₋₄₎-CONH₂ group;
- Tag₂ represents a peptide containing from 6 to 20 amino acids wherein at least three of these amino acids are selected from the group consisting of lysine and arginine, wherein the or each carboxy-terminal group of Tag₂ is a -COOH group or a -CONH₂ group;
- s represents 0 or 1;
- t represents 0 or 1;
- u represents 0 or 1;
- Aa₇₈ represents a proline, an alanine, a phenylalanine, an arginine or a glutamic acid residue, wherein the proline, alanine, phenylalanine, arginine or glutamic acid residue is optionally substituted by one, two or three substituents selected from a halogen atom and amino group and wherein Aa₇₈ is optionally alkylated with a C₁-C₄ alkyl group on the N at the peptidic bond; and
- G₁ represents a C₆₋₂₀ aryl group selected from a phenyl group, a naphthyl group, a biphenyl group and a binaphthyl group; or a 6-10 membered heteroaryl group selected from a pyridine group, an indolyl group and a quinoxaline group; wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from a C₁-C₄ alkyl group and a halogen atom.

3. A peptidic compound according to claims 1 to 2, wherein Aa₇₄ represents a direct bond, a leucine, a valine, a lysine, a proline, a 4-aminoproline or a 4-acetaminoproline residue, wherein (a) when Aa₇₄ is other than a direct bond it is optionally linked to Aa₈₅; and/or (b) when Aa₇₄ is leucine, the leucine residue is optionally alkylated with a methyl group on the N at the peptidic bond.

4. A peptidic compound according to claims 1 to 3, wherein Aa₇₅ represents a direct bond, a glutamine, a leucine, a lysine or a valine residue.

5. A peptidic compound according to any one of claims 1 to 4, wherein, when m is

5 1 and n is 1, L₁ represents a -C(O)-(CH₂)₂-NH- group.

6. A peptidic compound according to claim 1, wherein Tag₁ represents a -C(O)-

(CH₂)_r-CH₃ group, a -C(O)-(CH₂)₇-((E-CH=CH)-CH₂)₁-(CH₂)₆-CH₃ group, a -C(O)-

(CH₂)₇-((Z-CH=CH)-CH₂)₁-(CH₂)₆-CH₃ group or a -C(O)-(CH₂)₇-((Z-CH=CH)-CH₂)₃-

10 CH₃ group, wherein when Aa₇₄ represents a 4-aminoproline residue and m is 0, the Tag₁ group is linked to Aa₇₄ through the 4-amino substituent of the 4-aminoproline residue; and r represents 6 to 20.

7. A peptidic compound according to claim 6, wherein Tag₁ represents a -C(O)-

15 (CH₂)_r-CH₃ group, wherein when Aa₇₄ represents a 4-aminoproline residue and m is 0,

the Tag₁ group is linked to Aa₇₄ through the 4-amino substituent of the 4-aminoproline residue; and r represents 6 to 20.

8. A peptidic compound according to claim 1, wherein in -Aa₇₅-Aa₇₄-[L₁]_m-

20 [Tag₁]_n:

- Aa₇₄ represents a direct bond, a leucine, a valine, a lysine, a proline, a 4-aminoproline or a 4-acetaminoproline residue, wherein (a) when Aa₇₄ is other than a direct bond it is optionally linked to Aa₈₅; and/or (b) when Aa₇₄ is leucine, the leucine residue is optionally alkylated with a methyl group on the N at the peptidic bond (i.e. the leucine residue is optionally N-methylated at the peptidic bond);

25

- Aa₇₅ represents a direct bond, a glutamine, a leucine, a lysine or a valine residue;
- (i) m is 0 and n is 0; or (ii) m is 0 and n is 1; or (iii) m is 1 and n is 1, wherein when m and n each represent 0, and Aa₇₄ is not linked to Aa₈₅, the or each amino-terminal group of R¹ is typically a -NH₂ group and provided that when m and n each represent 0, Aa₇₄ and Aa₇₅ cannot simultaneously be a direct bond;
- L₁ represents a -C(O)-(CH₂)₂-NH- group;

30

- Tag₁ represents a $-\text{C}(\text{O})-(\text{CH}_2)_r-\text{CH}_3$ group, a $-\text{C}(\text{O})-(\text{CH}_2)_7-((E-\text{CH}=\text{CH})-\text{CH}_2)_1-(\text{CH}_2)_6-\text{CH}_3$ group, a $-\text{C}(\text{O})-(\text{CH}_2)_7-((Z-\text{CH}=\text{CH})-\text{CH}_2)_1-(\text{CH}_2)_6-\text{CH}_3$ group or a $-\text{C}(\text{O})-(\text{CH}_2)_7-((Z-\text{CH}=\text{CH})-\text{CH}_2)_3-\text{CH}_3$ group, wherein when Aa₇₄ represents a 4-aminoproline residue and m is 0, the Tag₁ group is linked to Aa₇₄ through the 4-amino substituent of the 4-aminoproline residue; and
- r represents 6 to 20.

9. A peptidic compound according to claim 8, wherein in $-\text{Aa}_{75}-\text{Aa}_{74}-[\text{L}_1]_m-[\text{Tag}_1]_n$:

- Aa₇₄ represents a direct bond, a leucine, a valine, a lysine, a proline, a 4-aminoproline or a 4-acetaminoproline residue, wherein (a) when Aa₇₄ is other than a direct bond it is optionally linked to Aa₈₅; and/or (b) when Aa₇₄ is leucine, the leucine residue is optionally alkylated with a methyl group on the N at the peptidic bond (i.e. the leucine residue is optionally N-methylated at the peptidic bond);
- Aa₇₅ represents a direct bond, a glutamine, a leucine, a lysine or a valine residue;
- (i) m is 0 and n is 0; or (ii) m is 0 and n is 1; or (iii) m is 1 and n is 1, wherein when m and n each represent 0, and Aa₇₄ is not linked to Aa₈₅, the or each amino-terminal group of R¹ is typically a $-\text{NH}_2$ group and provided that when m and n each represent 0, Aa₇₄ and Aa₇₅ cannot simultaneously be a direct bond;
- L₁ represents a $-\text{C}(\text{O})-(\text{CH}_2)_2-\text{NH}-$ group; and
- Tag₁ represents a $-\text{C}(\text{O})-(\text{CH}_2)_r-\text{CH}_3$ group, wherein when Aa₇₄ represents a 4-aminoproline residue and m is 0, the Tag₁ group is linked to Aa₇₄ through the 4-amino substituent of the 4-aminoproline residue; and
- r represents 6 to 20.

10. A peptidic compound according to any one of claims 1 to 9, wherein Tag₁ represents a $-\text{C}(\text{O})-(\text{CH}_2)_r-\text{CH}_3$ group, wherein when Aa₇₄ represents a 4-aminoproline residue and m is 0, the Tag₁ group is linked to Aa₇₄ through the 4-amino substituent of the 4-aminoproline residue; and r represents 6 or 16.

11. A peptidic compound according to any one of claims 1 to 10, wherein in $-\text{Aa}_{75}-\text{Aa}_{74}-[\text{L}_1]_m-[\text{Tag}_1]_n$:

- Aa₇₄ represents a direct bond, a leucine, a valine, a lysine, a proline, a 4-aminoproline or a 4-acetaminoproline residue, wherein (a) when Aa₇₄ is other than a direct bond it is optionally linked to Aa₈₅; and/or (b) when Aa₇₄ is leucine, the leucine residue is optionally alkylated with a methyl group on the N at the peptidic bond (i.e. the leucine residue is optionally N-methylated at the peptidic bond);
- Aa₇₅ represents a direct bond, a glutamine, a leucine, a lysine or a valine residue;
- (i) m is 0 and n is 0; or (ii) m is 0 and n is 1; or (iii) m is 1 and n is 1, wherein when m and n each represent 0, and Aa₇₄ is not linked to Aa₈₅, the or each amino-terminal group of R¹ is typically a –NH₂ group and provided that when m and n each represent 0, Aa₇₄ and Aa₇₅ cannot simultaneously be a direct bond;
- L₁ represents a –C(O)-(CH₂)₂-NH- group;
- Tag₁ represents a –C(O)-(CH₂)_r-CH₃ group, wherein when Aa₇₄ represents a 4-aminoproline residue and m is 0, the Tag₁ group is linked to Aa₇₄ through the 4-amino substituent of the 4-aminoproline residue; and
- r represents 6 or 16.

12. A peptidic compound according to any one of claims 1 to 11, wherein R¹ represents a –COCH₃ group or a –Aa₇₅-Aa₇₄-[L₁]_m-[Tag₁]_n group.

13. A peptidic compound according to any one of claims 1 to 12, wherein Aa₈₄ represents a direct bond, a leucine, a valine or a lysine residue, wherein, when Aa₈₄ is a leucine residue, Aa₈₄ is optionally alkylated with a methyl group on the N at the peptidic bond (i.e. the leucine is optionally N-methylated at the peptidic bond).

14. A peptidic compound according to any one of claims 1 to 13, wherein Aa₈₅ represents a direct bond, a proline, a leucine, a valine, a lysine, or a D-proline residue, wherein when Aa₈₅ is other than a direct bond it is optionally linked to Aa₇₄.

15. A peptidic compound according to any one of claims 1 to 14, wherein p is 1 and q is 1, L₂ represents a –NH-(CH₂)₂-CO- group.

16. A peptidic compound according to any one of claims 1 to 15, wherein Tag₂ is a cell penetrating peptide containing from 8 to 11 amino acids, wherein at least three of these amino acids are selected from the group consisting of lysine and arginine and wherein the or each carboxy-terminal group of Tag₂ is a –CONH₂ group.

5

17. A peptidic compound according to any one of claims 1 to 16, wherein in –Aa₈₄-Aa₈₅-[L₂]_p-[Tag₂]_q:

- Aa₈₄ represents a direct bond, a leucine, a valine or a lysine residue, wherein, when Aa₈₄ is a leucine residue, Aa₈₄ is optionally alkylated with a methyl group on the N at the peptidic bond (i.e. the leucine residue is optionally N-methylated at the peptidic bond);
- Aa₈₅ represents a direct bond, a proline, a leucine, a valine, a lysine, or a D-proline residue, wherein when Aa₈₅ is other than a direct bond it is optionally linked to Aa₇₄;
- (i) p is 0 and q is 0; or (ii) p is 1 and q is 1, wherein, when p and q each represent 0 and Aa₇₄ is not linked to Aa₈₅, the or each carboxy-terminal group of R² is a –COOH group or a –CONH₂ group and provided that when p and q each represent 0, Aa₈₄ and Aa₈₅ cannot simultaneously be a direct bond;
- L₂ represents a –NH-(CH₂)₂-CO- group; and
- Tag₂ is a peptide containing from 8 to 11 amino acids, wherein at least three of these amino acids are selected from the group consisting of lysine and arginine and the or each carboxy-terminal group of Tag₂ is a –CONH₂ group.

18. A peptidic compound according to any one of claims 1 to 17, wherein R² represents a –NH₂ group, or a –Aa₈₄-Aa₈₅-[L₂]_p-[Tag₂]_q group.

19. A peptidic compound according to claim 1, wherein:

- R¹ is selected from:
 - –COCH₃;
 - –CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
 - –CO-(CH₂)₂-NH-CO-(CH₂)₆-CH₃;
 - –Gln-Pro((4S))-NH-CO-(CH₂)₂₀-CH₃-;
 - –Gln-Pro((4S))-NH-CO-(CH₂)₁₈-CH₃-;


30

- -Gln-Pro((4S)-NH-CO-(CH₂)₁₇-CH₃)-;
- -Gln-Pro((4S)-NH-CO-(CH₂)₁₆-CH₃)-;
- -Gln-Pro((4S)-NH-CO-(CH₂)₁₄-CH₃)-;
- -Gln-Pro((4S)-NH-CO-(CH₂)₁₂-CH₃)-;
- 5 ○ -Gln-Pro((4S)-NH-CO-(CH₂)₁₀-CH₃)-;
- -Gln-Pro((4S)-NH-CO-(CH₂)₇-((E-CH=CH)-CH₂)₁-(CH₂)₆-CH₃)-;
- -Gln-Pro((4S)-NH-CO-(CH₂)₇-((Z-CH=CH)-CH₂)₁-(CH₂)₆-CH₃)-;
- -Gln-Pro((4S)-NH-CO-(CH₂)₇-((Z-CH=CH)-CH₂)₃-CH₃)- ;
- -Gln-Pro((4S)-NHC(O)CH₃)-;
- 10 ○ -Gln-Leu-H;
- -Gln-Leu-;
- -Gln-Leu-CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
- -Gln-Leu-CO-(CH₂)₂-NH-CO-(CH₂)₆-CH₃;
- -Gln-MeLeu-CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
- 15 ○ -Gln-Lys-CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
- -Gln-Lys(-CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃)-;
- -Gln-Lys(N⁶-CO-(CH₂)₁₆-CH₃)-;
- -Gln-Lys(-CO-(CH₂)₁₆-CH₃)-;
- -Gln-AcPro((4S)-NH-CO-(CH₂)₁₆-CH₃);
- 20 ○ -Gln-Pro-CO-(CH₂)₁₆-CH₃;
- -Leu-Leu-CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
- -Leu-Leu-H;
- -Lys-Lys-CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
- -Lys-Pro((4S)-NH-CO-(CH₂)₁₆-CH₃)- ; and
- 25 ○ -Val-Val- CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
- R² is selected from;
 - -NH₂;
 - -NH-(CH₂)₂-CO-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂;
 - -Leu-D-Pro-;
 - 30 ○ -Leu-D-Pro-NH₂;
 - -Leu-Leu-NH-(CH₂)₂-CO-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂;
 - -Leu-Leu-NH₂;

- -Leu-Pro-OH;
 - -Leu-Pro-NH₂;
 - -Leu-Pro-;
 - -Leu-Pro-NH-(CH₂)₂-CO-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-NH₂;
 - -Leu-Pro-NH-(CH₂)₂-CO-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-NH₂;
 - -Leu-Pro-NH-(CH₂)₂-CO-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂;
 - -Leu-Pro-NH-(CH₂)₂-CO-Tyr-Ala-Arg-Ala-Ala-Ala-Arg-Gln-Ala-Arg-Ala-NH₂;
 - -MeLeu-D-Pro-;
 - -MeLeu-Pro-NH₂;
 - -Lys-Lys-NH₂;
 - -Lys-D-Pro-; and
 - -Val-Val-NH₂;
 - either (i) s, t, and u each represent 0; or (ii) s, t, and u each represent 1;
 - Aa₇₈ represents an unsubstituted alanine, arginine, glutamic acid or L-thioprolino residue, or a proline or a phenylalanine residue optionally substituted by one substituent selected from a fluorine atom and amino group, and wherein Aa₇₈ is optionally alkylated with a methyl group on the N at the peptidic bond; and
 - G₁ represents an unsubstituted 6-10 membered heteroaryl group selected from a pyridine group, an indolyl group and a quinoxaline group; or a C₆₋₂₀ aryl group selected from a phenyl group, a naphthyl group, a biphenyl group and a binaphthyl group, which aryl group is optionally substituted by three or four substituents selected from a methyl group and a halogen atom; or a 4-6 membered saturated heterocyclyl group containing one oxygen atom selected from an oxetanyl group and a tetrahydro-2H-pyranyl group.
20. A peptidic compound according to any one of claims 1 to 19, wherein:
- R¹ is selected from:
 - -COCH₃;
 - -CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
 - -CO-(CH₂)₂-NH-CO-(CH₂)₆-CH₃;

- -Gln-Pro((4S)-NH-CO-(CH₂)₁₆-CH₃)-;
- -Gln-Pro((4S)-NHC(O)CH₃)-;
- -Gln-Leu-H;
- -Gln-Leu-;
- 5 ○ -Gln-Leu-CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
- -Gln-Leu-CO-(CH₂)₂-NH-CO-(CH₂)₆-CH₃;
- -Gln-MeLeu-CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
- -Gln-Lys-CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
- -Gln-Lys(-CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃)-;
- 10 ○ -Gln-AcPro((4S)-NH-CO-(CH₂)₁₆-CH₃);
- -Gln-Pro-CO-(CH₂)₁₆-CH₃;
- -Leu-Leu-CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
- -Leu-Leu-H;
- -Lys-Lys-CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃; and
- 15 ○ -Val-Val- CO-(CH₂)₂-NH-CO-(CH₂)₁₆-CH₃;
- R² is selected from;
 - -NH₂;
 - -NH-(CH₂)₂-CO-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂;
 - -Leu-D-Pro-;
 - 20 ○ -Leu-D-Pro-NH₂;
 - -Leu-Leu-NH-(CH₂)₂-CO-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂;
 - -Leu-Leu-NH₂;
 - -Leu-Pro-OH;
 - 25 ○ -Leu-Pro-NH₂;
 - -Leu-Pro-;
 - -Leu-Pro-NH-(CH₂)₂-CO-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-NH₂;
 - -Leu-Pro-NH-(CH₂)₂-CO-Arg-Arg-Arg-Arg-Arg-Arg-Arg-NH₂;
 - 30 ○ -Leu-Pro-NH-(CH₂)₂-CO-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂;
 - -Leu-Pro-NH-(CH₂)₂-CO-Tyr-Ala-Arg-Ala-Ala-Ala-Arg-Gln-Ala-Arg-Ala-NH₂;
 - -MeLeu-D-Pro-;

- -MeLeu-Pro-NH₂;
 - -Lys-Lys-NH₂; and
 - -Val-Val-NH₂;
 - either (i) s, t, and u each represent 0; or (ii) s, t, and u each represent 1;
- 5 • Aa₇₈ represents an unsubstituted alanine, arginine or glutamic acid residue, or a proline or a phenylalanine residue optionally substituted by one substituent selected from a fluorine atom and amino group, and wherein Aa₇₈ is optionally alkylated with a methyl group on the N at the peptidic bond; and
- 10 • G₁ represents an unsubstituted 6-10 membered heteroaryl group selected from a pyridine group, an indolyl group and a quinoxaline group; or a C₆₋₂₀ aryl group selected from a phenyl group, a naphthyl group, a biphenyl group and a binaphthyl group, which aryl group is optionally substituted by three or four substituents selected from a methyl group and a halogen atom.
- 15 21. A peptidic compound according to claim 1 wherein the peptidic compound is a compound of formula (IA)', or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof:




Formula (IA)'

wherein

- Aa₇₄ represents a leucine, a lysine, a 4-aminoproline or a 4-acetaminoproline residue;
- Aa₇₅ represents a glutamine or a lysine residue;
- m and n each independently represent an integer selected from 0 and 1;
- 5 • when m is 1 and n is 1 L₁ represents a -C(O)-(CH₂)₍₁₋₄₎-NH- group and when m is 1 and n is 0 L₁ represents a -C(O)-(CH₂)₍₁₋₄₎-NH₂ group;
- Tag₁ represents a -C(O)-(CH₂)_r-CH₃ group, a -C(O)-(CH₂)₇-((E-CH=CH)-CH₂)₁-(CH₂)₆-CH₃ group, a -C(O)-(CH₂)₇-((Z-CH=CH)-CH₂)₁-(CH₂)₆-CH₃ group or a -C(O)-(CH₂)₇-((Z-CH=CH)-CH₂)₃-CH₃ group, wherein when Aa₇₄ represents a 4-aminoproline residue and m is 0, the Tag₁ group is linked to Aa₇₄ through the 4-amino substituent of the 4-aminoproline residue;
- 10 • r represents an integer selected from 6 to 20;
- Aa₈₄ represents a leucine residue or a lysine residue, wherein the leucine residue is optionally N-methylated at the peptidic bond;
- 15 • Aa₈₅ represents a proline or a D-proline residue;
- s represents 0 or 1;
- t represents 0 or 1;
- u represents 0 or 1;
- Aa₇₈ represents a proline, a L-thiopline, an alanine, an arginine, or a glutamic acid residue, wherein the proline, L-thiopline, alanine, arginine or glutamic acid residue is optionally substituted by one or two substituents selected from a halogen atom and amino group; and
- 20 • G₁ represents a phenyl group, a pyridine group or an indolyl group; wherein the phenyl, pyridine and indolyl groups are optionally substituted by one, two, three or four substituents selected from a C₁-C₄ alkyl group and a halogen atom; or a 4-6 membered saturated heterocyclyl group containing one oxygen atom selected from an oxetanyl group and a tetrahydro-2H-pyranyl group.
- 25
- 22. A peptidic compound of formula (IA)' according to claim 21 wherein:
- 30 • Tag₁ represents a -C(O)-(CH₂)_r-CH₃ group, wherein when Aa₇₄ represents a 4-aminoproline residue and m is 0, the Tag₁ group is linked to Aa₇₄ through the 4-amino substituent of the 4-aminoproline residue; and

- r represents an integer selected from 6 to 20.

23. A peptidic compound according to any one of claims 1 to 22, wherein the peptidic compound is a compound of formula (IA), or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof:



Formula (IA)

wherein

- Aa₇₄ represents a leucine, a lysine, a 4-aminoproline or a 4-acetaminoproline residue;
- Aa₇₅ represents a glutamine residue;
- m and n each independently represent an integer selected from 0 and 1;
- when m is 1 and n is 1 L₁ represents a $-\text{C}(\text{O})-(\text{CH}_2)_{(1-4)}-\text{NH}-$ group and when m is 1 and n is 0 L₁ represents a $-\text{C}(\text{O})-(\text{CH}_2)_{(1-4)}-\text{NH}_2$ group;
- Tag₁ represents a $-\text{C}(\text{O})-(\text{CH}_2)_r-\text{CH}_3$ group, wherein when Aa₇₄ represents a 4-aminoproline residue and m is 0, the Tag₁ group is linked to Aa₇₄ through the 4-amino substituent of the 4-aminoproline residue;
- r represents an integer selected from 6 to 18;
- Aa₈₄ represents a leucine residue wherein the leucine residue is optionally N-methylated at the peptidic bond;
- Aa₈₅ represents a proline or a D-proline residue;

- s represents 0 or 1;
- t represents 0 or 1;
- u represents 0 or 1;
- Aa₇₈ represents a proline, an alanine, an arginine or a glutamic acid residue, wherein the proline, alanine, arginine or glutamic acid residue is optionally substituted by one or two substituents selected from a halogen atom and amino group; and
- G₁ represents a phenyl group or an indolyl group; wherein the phenyl and indolyl groups are optionally substituted by one, two, three or four substituents selected from a C₁-C₄ alkyl group and a halogen atom.

24. A peptidic compound according to claim 1, wherein the peptidic compound has a sequence selected from:

H-Leu-Gln-Trp(indol-2-yl-&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&¹)-Leu-Pro-OH (SEQ ID NO: 1)

{[H-Leu-Gln-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,4-phenylenediyl)dimethylene&²]} (SEQ ID NO: 2)

{[H-Leu-Gln-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 3)

{[&¹Leu-Gln-Cys(&²)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&³)-Leu-Pro&¹] [&²(1,3-phenylenediyl)dimethylene&³]} (SEQ ID NO: 4)

{[&¹Leu-Gln-Cys(&²)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&³)-Leu-Pro&¹] [&²(1,4-phenylenediyl)dimethylene&³]} (SEQ ID NO: 5)

{[Acetyl-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 6)

Acetyl-Trp(indol-2-yl-&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&¹)-NH₂ (SEQ ID NO: 7)

H-Leu-Gln-Trp(indol-2-yl-&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&¹)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂ (SEQ ID NO: 8)

{[H-Leu-Gln-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-

Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 9)

Acetyl-Phe(*p*-&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&¹)-NH₂ (SEQ ID NO: 10)

- &¹Leu-Gln-Trp(indol-2-yl-&²)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro&¹ (SEQ ID NO: 11)
- {[Acetyl-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 12)
- 5 {[H-Leu-Gln-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Tyr-Ala-Arg-Ala-Ala-Ala-Arg-Gln-Ala-Arg-Ala-NH₂] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 13)
- {[H-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 14)
- 10 {[H-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Tyr-Ala-Arg-Ala-Ala-Ala-Arg-Gln-Ala-Arg-Ala-NH₂] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 15)
- {[H-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 16)
- 15 {[&¹Leu-Gln-Cys(&²)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&³)-Leu-Pro&¹] [&²(1,3-phenylenediyl)dimethylene&³]} (SEQ ID NO: 17)
- {[H-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 18)
- 20 {[H-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 19)
- {[Acetyl-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-NH₂]-[&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 20)
- 25 {[Acetyl-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 21)
- Acetyl-Phe(*m*-&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&¹)-NH₂ (SEQ ID NO: 22)
- Acetyl-Phe(*o*-&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&¹)-NH₂ (SEQ ID NO: 23)
- {[Acetyl-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,1'-biphenyl)2,2'-diyl]dimethylene&²]} (SEQ ID NO: 24)
- 30 {[Acetyl-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,1'-binaphthalene)2,2'-diyl]dimethylene&²]} (SEQ ID NO: 25)

- {[Acetyl-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(quinoxaline)2,3-diylldimethylene&²]} (SEQ ID NO: 26)
- {[Acetyl-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(naphthalene)2,3-diylldimethylene&²]} (SEQ ID NO: 27)
- 5 {[Stearyl-βAla-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 28)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 29)
- {[H-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂] [&¹(naphthalene)2,3-diylldimethylene&²]} (SEQ ID NO: 30)
- 10 {[Stearyl-βAla-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 31)
- {[Stearyl-βAla-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(naphthalene)2,3-diylldimethylene&²]} (SEQ ID NO: 32)
- 15 {[Stearyl-βAla-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 33)
- {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 34)
- 20 {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 35)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(naphthalene)2,3-diylldimethylene&²]} (SEQ ID NO: 36)
- 25 {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 37)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(naphthalene)2,3-diylldimethylene&²]} (SEQ ID NO: 38)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 39)
- 30 Stearyl-βAla-Leu-Gln-Phe(*m*-&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&¹)-Leu-Pro-OH (SEQ ID NO: 40)

- Stearyl-βAla-Phe(*m*-&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&¹)-NH₂ (SEQ ID NO: 41)
- {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(naphthalene)2,3-diyl dimethylene&²]} (SEQ ID NO: 42)
- 5 {[Acetyl-Cys(&¹)-Asp-MeAla-Glu-Thr-Gly-Glu-Cys(&²)-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 43)
- {[Stearyl-βAla-Leu-Leu-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Leu-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 44)
- {[Stearyl-βAla-MeLeu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 45)
- 10 {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-MeLeu-Pro-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 46)
- {[Stearyl-βAla-Lys-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 47)
- 15 {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 48)
- {[Stearyl-βAla-Lys(&¹)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 49)
- {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 50)
- 20 {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(1,3,5-trimethylbenzene)2,4-diyl dimethylene&²]} (SEQ ID NO: 51)
- {[Stearyl-βAla-Val-Val-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Val-Val-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 52)
- 25 {[Stearyl-βAla-Lys-Lys-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Lys-Lys-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 53)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 54)
- 30 {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(3,4,5,6-tetrafluorobenzene)1,2-diyl dimethylene&²]} (SEQ ID NO: 55)

- {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(3,4,5,6-tetrafluorobenzene)1,2-diylldimethylene&²]} (SEQ ID NO: 56)
- 5 {[Stearyl-βAla-Lys-Lys-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 57)
- {[H-Leu-Leu-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Leu-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(naphthalene)2,3-diylldimethylene&²]} (SEQ ID NO: 58)
- 10 {[H-Leu-Leu-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Leu-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,3,5-trimethylbenzene)2,4-diylldimethylene&²]} (SEQ ID NO: 59)
- {[H-Leu-Leu-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Leu-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 60)
- 15 {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(quinoxaline)2,3-diylldimethylene&²]} (SEQ ID NO: 61)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(pyridine)2,6-diylldimethylene&²]} (SEQ ID NO: 62)
- {[H-Leu-Leu-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Leu-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,1'-binaphthalene)2,2'-diylldimethylene&²]} (SEQ ID NO: 63)
- 20 {[&¹Pro((4S)-NH-Acetyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 64)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(pyridine)3,5-diylldimethylene&²]} (SEQ ID NO: 65)
- 25 {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,1'-binaphthalene)2,2'-diylldimethylene&²]} (SEQ ID NO: 66)
- {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,3,5-trimethylbenzene)2,4-diylldimethylene&²]} (SEQ ID NO: 67)
- 30

- {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg₈-NH₂][&¹(naphthalene)2,3-diyl dimethylene&²]} (SEQ ID NO: 68)
- {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg₁₀-NH₂][&¹(naphthalene)2,3-diyl dimethylene&²]} (SEQ ID NO: 69)
- 5 {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Arg-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 70)
- {[H-Leu-Gln-Cys(&¹)-Asp-Phe(4-F)-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 71)
- 10 {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro((4S)-F)-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 72)
- {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro((4S)-NH₂)-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 73)
- {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,3-phenylenediyl)dimethylene&³]} (SEQ ID NO: 74)
- 15 {[Acetyl-Pro((4S)-NH-Stearyl)-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-D-Pro-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 75)
- {[Stearyl-Pro-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-D-Pro-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 76)
- 20 {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-MeLeu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 77)
- {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Thz-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 78)
- {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(3,3-oxetanediyl)dimethylene&³]} (SEQ ID NO: 79)
- 25 {[&¹Pro((4S)-NH-Miristoyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 80)
- {[&¹Pro((4S)-NH-Stearyl)-Lys-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 81)
- 30 {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Lys-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 82)
- {[&¹Pro((4S)-NH-Palmitoyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 83)

- {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&¹(pyridine)3,5-diyl dimethylene&²]} (SEQ ID NO: 84)
- {[&¹Pro((4S)-NH-Lauryl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 85)
- 5 {[&¹Pro((4S)-NH- α -linolenyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 86)
- {[&¹Pro((4S)-NH-elaidyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 87)
- {[&¹Pro((4S)-NH-oleyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 88)
- 10 {[&¹Pro((4S)-NH-behenyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 89)
- {[&¹Pro((4S)-NH-arachidyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 90)
- 15 {[&¹Lys(N⁶-Stearyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 91)
- {[Stearyl-Lys(&¹)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 92)
- {[&¹Pro((4S)-NH-Arachidyl)-Gln-Cys(&²)-Asp-Thz-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 93)
- 20 {[&¹Pro((4S)-NH-Arachidyl)-Gln-Cys(&²)-Asp-Thz-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(3,3-oxetanediyl)dimethylene&³]} (SEQ ID NO: 94)
- {[&¹Pro((4S)-NH-Arachidyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(3,3-oxetanediyl)dimethylene&³]} (SEQ ID NO: 95)
- 25 {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Thz-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,3-phenylenediyl)dimethylene&³]} (SEQ ID NO: 96)
- {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Thz-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(3,3-oxetanediyl)dimethylene&³]} (SEQ ID NO: 97)
- {[&¹Pro((4S)-NH-Nonadecanoyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 98)
- 30 {[Stearyl- β Ala-Leu-Leu-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Leu-NH₂][&¹(3,3-oxetanediyl)dimethylene&²]} (SEQ ID NO: 99)

{[&¹Pro((4*S*)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹] [&²(tetrahydro-2*H*-pyran-4,4-diyl)dimethylene&³]} (SEQ ID NO: 100)
or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof.

- 5 25. A peptidic compound according to claim 1 to 24, wherein the peptidic compound has a sequence selected from:

H-Leu-Gln-Trp(indol-2-yl-&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&¹)-Leu-Pro-OH (SEQ ID NO: 1)

- 10 {[H-Leu-Gln-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,4-phenylenediyl)dimethylene&²]} (SEQ ID NO: 2)

{[H-Leu-Gln-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 3)

- 15 {[&¹Leu-Gln-Cys(&²)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&³)-Leu-Pro&¹] [&²(1,3-phenylenediyl)dimethylene&³]} (SEQ ID NO: 4)

{[&¹Leu-Gln-Cys(&²)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&³)-Leu-Pro&¹] [&²(1,4-phenylenediyl)dimethylene&³]} (SEQ ID NO: 5)

{[Acetyl-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 6)

- 20 Acetyl-Trp(indol-2-yl-&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&¹)-NH₂ (SEQ ID NO: 7)

H-Leu-Gln-Trp(indol-2-yl-&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&¹)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂ (SEQ ID NO: 8)

- 25 {[H-Leu-Gln-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 9)

Acetyl-Phe(*p*-&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&¹)-NH₂ (SEQ ID NO: 10)

&¹Leu-Gln-Trp(indol-2-yl-&²)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro&¹ (SEQ ID NO: 11)

- 30 {[Acetyl-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 12)

{[H-Leu-Gln-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Tyr-Ala-Arg-Ala-Ala-Ala-Arg-Gln-Ala-Arg-Ala-NH₂] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 13)

- {[H-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 14)
- {[H-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Tyr-Ala-Arg-Ala-Ala-Ala-Arg-Gln-Ala-Arg-Ala-NH₂] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 15)
- {[H-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 16)
- {[&¹Leu-Gln-Cys(&²)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&³)-Leu-Pro&¹] [&²(1,3-phenylenediyl)dimethylene&³]} (SEQ ID NO: 17)
- {[H-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 18)
- {[H-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO:19)
- {[Acetyl-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-NH₂]-[&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO:20)
- {[Acetyl-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 21)
- Acetyl-Phe(*m*-&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&¹)-NH₂ (SEQ ID NO: 22)
- Acetyl-Phe(*o*-&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&¹)-NH₂ (SEQ ID NO: 23)
- {[Acetyl-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,1'-biphenyl)2,2'-diyldimethylene&²]} (SEQ ID NO: 24)
- {[Acetyl-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,1'-binaphthalene)2,2'-diyldimethylene&²]} (SEQ ID NO: 25)
- {[Acetyl-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(quinoxaline)2,3-diyl dimethylene&²]} (SEQ ID NO: 26)
- {[Acetyl-Cys(&¹)-Asp-Glu-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(naphthalene)2,3-diyl dimethylene&²]} (SEQ ID NO: 27)
- {[Stearyl-βAla-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 28)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 29)

- {[H-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂] [&¹(naphthalene)2,3-diyl dimethylene&²]} (SEQ ID NO: 30)
- 5 {[Stearyl-βAla-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 31)
- {[Stearyl-βAla-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(naphthalene)2,3-diyl dimethylene&²]} (SEQ ID NO: 32)
- {[Stearyl-βAla-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 33)
- 10 {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 34)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 35)
- 15 {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(naphthalene)2,3-diyl dimethylene&²]} (SEQ ID NO: 36)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 37)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(naphthalene)2,3-diyl dimethylene&²]} (SEQ ID NO: 38)
- 20 {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Ala-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-OH] [&¹(1,3-phenylenediyl)dimethylene&²]} (SEQ ID NO: 39)
- Stearyl-βAla-Leu-Gln-Phe(*m*-&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&¹)-Leu-Pro-OH (SEQ ID NO: 40)
- 25 Stearyl-βAla-Phe(*m*-&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&¹)-NH₂ (SEQ ID NO: 41)
- {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(naphthalene)2,3-diyl dimethylene&²]} (SEQ ID NO: 42)
- {[Acetyl-Cys(&¹)-Asp-MeAla-Glu-Thr-Gly-Glu-Cys(&²)-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 43)
- 30 {[Stearyl-βAla-Leu-Leu-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Leu-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 44)

- {[Stearyl-βAla-MeLeu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 45)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-MeLeu-Pro-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 46)
- 5 {[Stearyl-βAla-Lys-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 47)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 48)
- {[Stearyl-βAla-Lys(&¹)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-Pro&¹] [&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 49)
- 10 {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹] [&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 50)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(1,3,5-trimethylbenzene)2,4-diyl]dimethylene&²]} (SEQ ID NO: 51)
- 15 {[Stearyl-βAla-Val-Val-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Val-Val-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 52)
- {[Stearyl-βAla-Lys-Lys-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Lys-Lys-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 53)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 54)
- 20 (SEQ ID NO: 54)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(3,4,5,6-tetrafluorobenzene)1,2-diyl]dimethylene&²]} (SEQ ID NO: 55)
- {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(3,4,5,6-tetrafluorobenzene)1,2-diyl]dimethylene&²]} (SEQ ID NO: 56)
- 25 (SEQ ID NO: 56)
- {[Stearyl-βAla-Lys-Lys-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂] [&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 57)
- {[H-Leu-Leu-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Leu-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(naphthalene)2,3-diyl]dimethylene&²]} (SEQ ID NO: 58)
- 30 (SEQ ID NO: 58)

- {[H-Leu-Leu-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Leu-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,3,5-trimethylbenzene)2,4-diyl dimethylene&²]} (SEQ ID NO: 59)
- 5 { [H-Leu-Leu-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Leu-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 60)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(quinoxaline)2,3-diyl dimethylene&²]} (SEQ ID NO: 61)
- 10 {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(pyridine)2,6-diyl dimethylene&²]} (SEQ ID NO: 62)
- {[H-Leu-Leu-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Leu-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,1'-binaphthalene)2,2'-diyl dimethylene&²]} (SEQ ID NO: 63)
- 15 {[&¹Pro((4S)-NH-Acetyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 64)
- {[Stearyl-βAla-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-NH₂][&¹(pyridine)3,5-diyl dimethylene&²]} (SEQ ID NO: 65)
- {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,1'-binaphthalene)2,2'-diyl dimethylene&²]} (SEQ ID NO: 66)
- 20 {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,3,5-trimethylbenzene)2,4-diyl dimethylene&²]} (SEQ ID NO: 67)
- {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg₈-NH₂][&¹(naphthalene)2,3-diyl dimethylene&²]} (SEQ ID NO: 68)
- 25 {[H-Leu-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg₁₀-NH₂][&¹(naphthalene)2,3-diyl dimethylene&²]} (SEQ ID NO: 69)
- {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Arg-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 70)
- 30 {[H-Leu-Gln-Cys(&¹)-Asp-Phe(4-F)-Glu-Thr-Gly-Glu-Cys(&²)-Leu-Pro-βAla-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH₂][&¹(1,2-phenylenediyl)dimethylene&²]} (SEQ ID NO: 71)

{[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro((4S)-F)-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 72)

{[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro((4S)-NH₂)-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 73)

5 {[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-Leu-D-Pro&¹][&²(1,3-phenylenediyl)dimethylene&³]} (SEQ ID NO: 74)

{[Acetyl-Pro((4S)-NH-Stearyl)-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-D-Pro-NH₂][&¹(1,2-phenylenediyl)dimethylene²]} (SEQ ID NO: 75)

10 {[Stearyl-Pro-Gln-Cys(&¹)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&²)-Leu-D-Pro-NH₂][&¹(1,2-phenylenediyl)dimethylene²]} (SEQ ID NO: 76)

{[&¹Pro((4S)-NH-Stearyl)-Gln-Cys(&²)-Asp-Pro-Glu-Thr-Gly-Glu-Cys(&³)-MeLeu-D-Pro&¹][&²(1,2-phenylenediyl)dimethylene&³]} (SEQ ID NO: 77)

or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof.

15 26. A pharmaceutical composition comprising a peptidic compound as defined in any one of claims 1 to 25 together with one or more pharmaceutically acceptable carriers and/or excipients.

27. A peptidic compound as defined in claims 1 to 25 or a pharmaceutical
20 composition as defined in claim 26 for use in therapy.

28. A peptidic compound as defined in claims 1 to 25 or a pharmaceutical composition as defined in claim 26 for use in therapy for the treatment of a pathological condition or disease associated with the activation of the Nrf2 pathway.

25

29. Use of a peptidic compound as defined in claims 1 to 25 or a pharmaceutical composition as defined in claim 26 in the manufacture of a medicament for treating a pathological condition or disease selected from the group consisting of Parkinson's disease, depression, Alzheimer's disease, atherosclerosis, heart failure, myocardial
30 infarction, diabetes, cancer, COPD, COPD exacerbations, acute lung injury, radiation-induced dermatitis, chemical induced dermatitis, contact induced dermatitis, Epidermolysis bullosa simplex, Pachyonychia congenital, Hailey-Hailey, vitiligo, photoaging and photodamaged skin.